ALLMedicine™ Hepatitis C Virus Center

Mar 28th, 2023 - The lack of robust immunocompetent animal models for hepatitis C virus (HCV) impedes vaccine development and studies of immune responses. Norway rat hepacivirus (NrHV) infection in rats shares HCV-defining characteristics, including hepatotropism,...

Mar 25th, 2023 - Patients with hepatitis C virus (HCV) undergoing primary elective total joint arthroplasty (TJA) are at increased risk of postoperative complications. Patients with chronic liver disease and cirrhosis, specifically Child-Pugh Class B and C, who ar...

Mar 19th, 2023 - The country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and 5.4%, respectively. This analysis reports hepat...

Mar 18th, 2023 - BackgroundTreatment with medications for opioid use disorder (MOUD) may improve hepatitis C virus (HCV) treatment outcomes by providing additional contact with health care professionals to support patient engagement. Objective: We describe a pharm...

Mar 18th, 2023 - England has committed to the World Health Organization target to eliminate hepatitis C virus (HCV) as a public threat by the year 2030. Given successful treatments for HCV in recent years, it is unclear whether HCV reinfection will impact England'...

Nov 22nd, 2022 - Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidn...

Aug 1st, 2021 - Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Clinical care for patients with HCV-related liver disease has advanced considerably with developments in screening, diagnostic procedures to evaluate liver fibrosis and i...

Sep 22nd, 2020 - Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an...

Mar 3rd, 2020 - Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, in...

Sep 24th, 2019 - This article has been corrected. The original version (PDF) is appended to this article as a Supplement. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatmen...

Dec 9th, 2022 - WASHINGTON, DC — "We don't get to use the 'eliminate' word all that often with a disease that's taking thousands or tens of thousands — or worldwide, hundreds of thousands — of lives every year, but we have that opportunity with hepatitis C." Dr F...

Nov 8th, 2022 - Vaccination campaigns in more than 80 nations have successfully reduced the prevalence of hepatitis B virus (HBV) surface antigen. That’s the good news. Less good is the news that no countries are on track to meet the goals for HBV eradication by ...

Aug 22nd, 2022 - Patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) and antiretrovirals (ARVs) for HIV rarely receive drug combinations that are contraindicated, according to real-world data from the EuroSIDA study. Modern DAA therap...

Aug 12th, 2022 - Fewer than 1 in 3 people infected with hepatitis C virus (HCV) begin receiving treatment within a year of their diagnosis, according to a new report by the Centers for Disease Control and Prevention (CDC). Although HCV infection can be cured in mo...

May 24th, 2022 - SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompen...